Ultimovacs - FOCUS - first in series of upcoming catalysts
Ultimovacs has announced that patient enrolment has been completed for FOCUS, the Phase II clinical trial assessing UV1 in combination with pembrolizumab for the treatment of head and neck cancer. The anticipated H224 top-line results, including overall survival (OS), represents a notable catalyst for the company as it comes amid several crucial readouts from Ultimovacs’s ongoing Phase II trials investigating the company’s lead cancer vaccine in various cancer indications. The INITIUM study is the next expected update (H223), assessing UV1 in combination with ipilimumab and nivolumab for the treatment of metastatic malignant melanoma.Ultimovacs ASA Formerly known as Ultimovacs AS. Ultimovacs ASA, formerly Ultimovacs AS, is a Norway-based pharmaceutical company developing immunotherapies against cancer. The Company's lead product candidate is UV1, a peptide-based vaccine inducing a specific T cell response against the universal cancer antigen telomerase. UV1 is being developed as a therapeutic cancer vaccine which may serve as a platform for use in combination with other immuno-oncology drugs which require an ongoing T cell response for their mode of action. The Company is performing a broad clinical development program with clinical trials in Europe and the USA.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.